Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Leukemia 2Philadelphia Chromosome 1Leukemia, Myeloid 1HER2+ Metastatic Breast Cancer 1Bronchiolitis Obliterans Syndrome 1Blast Crisis 1

Interventions

Cyclophosphamide 5fludarabine 4Mycophenolic Acid 4fludarabine phosphate 3blinatumomab 3Whole-Body Irradiation 3Tacrolimus 3Busulfan 3asciminib 2Rituximab 2Inotuzumab Ozogamicin 2Cytarabine 2Cyclosporine 2venetoclax 1tocilizumab 1ruxolitinib 1ricolinostat 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1nilotinib 1idelalisib 1ibrutinib 1ceralasertib 1Vincristine 1Thiotepa 1Surveys and Questionnaires 1Prednisone 1Midazolam 1Methotrexate 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia × asciminib × 30 days × Clear all
NCT05456191 2026-05-27

ASC4START

Novartis

Phase 3 Active not recruiting
568 enrolled 11 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07354074 2026-05-26

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Novartis

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡